

Retail prices of ACTs co-paid by the AMFm and other antimalarial medicines.

Reports of price-tracking surveys.

Overview

The independent price-tracking surveys were commissioned to give an interim perspective on two aspects of AMFm Phase 1: (i) availability and (ii) retail prices of co-paid ACTs. They are intended primarily to facilitate in-country discussions by implementers, technical partners and the Global Fund, with a view to informing adjustments as and when appropriate during AMFm Phase 1.

The operational aims of AMFm Phase 1 include influencing the market to reduce the retail prices of AMFm co-paid ACTs so that, over time, they will become price-competitive with those of antimalarials that are not co-paid by the AMFm.

AMFm Phase 1 is not a command-and-control exercise at the retail level. Therefore, while suggested retail prices indicate locally determined targets, the actual prices may vary across and within countries.

These surveys do not substitute in scope or depth for the independent evaluation.

For indications of what performance might be expected after one year of in-country implementation, please refer to the report on Estimating Benchmarks of Success in AMFm Phase 1 (available at <http://www.theglobalfund.org/en/amfm/>).